Hepatic Encephalopathy – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Hepatic Encephalopathy – Pipeline Review, H1 2017’, provides an overview of the Hepatic Encephalopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy

The report reviews pipeline therapeutics for Hepatic Encephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hepatic Encephalopathy therapeutics and enlists all their major and minor projects

The report assesses Hepatic Encephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hepatic Encephalopathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatic Encephalopathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Cosmo Pharmaceuticals NV

KannaLife Sciences Inc

Ocera Therapeutics Inc

Rebiotix Inc

Spherium Biomed SL

Umecrine Cognition AB

Versantis AG

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatic Encephalopathy - Overview

Hepatic Encephalopathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hepatic Encephalopathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatic Encephalopathy - Companies Involved in Therapeutics Development

Cosmo Pharmaceuticals NV

KannaLife Sciences Inc

Ocera Therapeutics Inc

Rebiotix Inc

Spherium Biomed SL

Umecrine Cognition AB

Versantis AG

Hepatic Encephalopathy - Drug Profiles

GR-3027 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KLS-13019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ornithine phenylacetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBX-2477 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rifamycin CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THDP-17 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatic Encephalopathy - Dormant Projects

Hepatic Encephalopathy - Discontinued Products

Hepatic Encephalopathy - Product Development Milestones

Featured News & Press Releases

Jan 30, 2017: Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy

Jan 05, 2017: Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis

Dec 07, 2016: Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy

Nov 03, 2016: Karolinska Development company Umecrine Cognition announces positive Phase 1 data with GR3027 in hepatic encephalopathy

Nov 02, 2016: Ocera Therapeutics: Update on OCR-002

Sep 19, 2016: Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy

Apr 15, 2016: Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL)

Apr 11, 2016: Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology

Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy

Dec 09, 2015: Umecrine Cognition Announces Grant Of a US Patent Protecting Its Lead Candidate Drug GR3027

Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy

Sep 16, 2015: Ocera Initiates Phase 1 Clinical Trial of Oral Drug Candidate OCR-002 for Prevention of Hepatic Encephalopathy

Aug 19, 2015: Umecrine Cognition announces the publication of preclinical results of the candidate drug GR3027 aimed for the treatment of hepatic encephalopathy

Aug 11, 2015: Kannalife Sciences Discusses Orphan Drug Opportunity for KLS-13019

Apr 01, 2015: Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hepatic Encephalopathy, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hepatic Encephalopathy – Pipeline by Cosmo Pharmaceuticals NV, H1 2017

Hepatic Encephalopathy – Pipeline by KannaLife Sciences Inc, H1 2017

Hepatic Encephalopathy – Pipeline by Ocera Therapeutics Inc, H1 2017

Hepatic Encephalopathy – Pipeline by Rebiotix Inc, H1 2017

Hepatic Encephalopathy – Pipeline by Spherium Biomed SL, H1 2017

Hepatic Encephalopathy – Pipeline by Umecrine Cognition AB, H1 2017

Hepatic Encephalopathy – Pipeline by Versantis AG, H1 2017

Hepatic Encephalopathy – Dormant Projects, H1 2017

Hepatic Encephalopathy – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Hepatic Encephalopathy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports